On Wednesday, World Health Organisation (WHO) said it expects to receive clarifications from Bharat Biotech by the end of this week on its COVID-19 vaccine, Covaxin and will meet on November 3 for a final risk-benefit assessment for the Emergency Use Listing.

• NTPC Green Energy Adds 50 MW Solar Power in Rajasthan
• Coffee Day Enterprises Settles Rs 25 Cr Loan With Kemfin
• GST Collections Rise 14.7% to Rs 2.04 Lakh Crore in September
• GPT Infraprojects Bags Rs 385 Cr South Africa Rail Order
• Cabinet Backs Rs 1.86 Lakh Cr Plan for Green Power Grid

WHO Technical Advisory Group for Emergency Use Listing (EUL) is an independent advisory group that provides recommendations to WHO on whether a #COVID19 vaccine can be listed for emergency use under the EUL procedure, the WHO tweeted.

The Technical Advisory Group met on October 26 and decided that additional clarifications from the manufacturer (Bharat Biotech) are needed to conduct a final EUL risk-benefit assessment for global use of the Covaxin vaccine”.

The Technical Advisory Group expects to receive these clarifications from the manufacturer (Bharat Biotech) by the end of this week. It aims to reconvene for the final risk-benefit assessment on Wednesday, November 3, 2021, the WHO tweeted.